ACTUATE THERAPEUTICS, INC.
ACTUNext catalyst
FOLFIRNINOX
Pancreatic Adenocarcinoma
Get an email about ACTU's next catalysts
Track ACTUATE THERAPEUTICS (ACTU) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ACTU Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd
FOLFIRNINOX Phase 2 Est. Readout
Estimated primary completion for FOLFIRNINOX trial (NCT05077800) in Pancreatic Adenocarcinoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
9-ING-41
Cancer
FOLFIRNINOX
Pancreatic Adenocarcinoma
Carboplatin
Salivary Gland Cancer
Gemcitabine - 21 day cycle
Cancer
Gemcitabine - 28 day cycle
Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
9-ING-41 | Phase 2 | Cancer | - | - |
FOLFIRNINOX | Phase 2 | Pancreatic Adenocarcinoma | - | - |
Carboplatin | Phase 2 | Salivary Gland Cancer | - | - |
Gemcitabine - 21 day cycle | Phase 2 | Cancer | - | - |
Gemcitabine - 28 day cycle | Phase 2 | Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ACTUATE THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in ACTUATE THERAPEUTICS, INC.'s (ACTU) pipeline across Phase 2. Its lead program is FOLFIRNINOX (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ACTUATE THERAPEUTICS, INC.'s next FDA catalyst?→
ACTUATE THERAPEUTICS, INC.'s (ACTU) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACTU biotech catalysts?→
Add ACTU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACTUATE THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.